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Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S212fared well (4/7 with DLBCL and 2/3 other B-cell lymphomas
and 2/2 other T-cell lymphomas are alive and disease free).
Patients in CR or PR had a better OS (18/23) compared with
those patients with persistent or progressive disease at time
of transplant (0/5). 11/29 patients died (9 from relapse and 2
from treatment related mortality).
Conclusions: HSCT offers the possibility of cure for patients
with NHL, especially for patients with ALCL and for those
patients that have a good response to re-induction therapy
prior to transplant. Relapsed disease post-transplant remains
a major challenge for patients with LL and for patients
transplanted with non-responsive disease. Post transplant
therapies to target residual disease should be evaluated in
these patients.280
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Introduction: Infections with NTM species are reported in
immunocompromised patients (pts) post-HCT with little
information on associated risk factors. In HIV+ pts, routine
prophylaxis is indicated for those with CD4 counts of 100-
200cells/uL. We hypothesize CD4 counts 200 as a possible
risk factor for development of NTM infection in the pediatric
alloHCT setting. We report our center’s experience with NTM
infections to help identify risk factors, clinical signiﬁcance
and need for prophylactic therapy.
Methods: Pts 21 years undergoing HCT from 2001 to 2014
were included. Deﬁnition of NTM infection: Positive culture
for NTM species in blood, cerebrospinal ﬂuid (CSF), lungs, BM
or tissue. Only pts withMycobacterium Avium Complex (MAC)
infection were included. Controls (n¼19) were identiﬁed by
matching age, gender, and underlying disease. Descriptive
statistics was calculated and comparison between 2 groups
was carried with t-test for continuous variables and Fisher
exact test for categorical variables.
Results: Of 272 pts undergoing HCT, NTM was diagnosed in
11 pts with 17 HCT (autologous¼1; allogeneic¼16) per-
formed among these pts. Indications for HCT: malignant¼6
(55%), non-malignant¼5 (45%). Donor sources: sibling BM
(n¼3), sibling PB (n¼2), unrelated PB (n¼3) unrelated BM
(n¼3), or unrelated UCB (n¼5). Conditioning regimens:
myeloablative (n¼7), non-myeloablative (n¼6), no condi-
tioning (n¼3). Pts had MAC isolated from the following sites:
lungs (n¼5), CSF (n¼1), BM (n¼2), lymph node (n¼1), and
blood (n¼3). Median date from HCT to NTM diagnosis was
233 days (range: 15 to 724 days). Mean absolute CD4 count at
diagnosis was 137 +/- 143 cells/uL (1 unreported). All pts
began therapy with azithromycin, ethambutol, and rifabutin/
rifampin. Additive therapy included levoﬂoxacin (n¼3),
imipenem (n¼1), amikacin (n¼3), and gatiﬂoxacin (n¼1).
Treatment duration ranged from 53-459 days. Eight of 11 pts
had graft-vs-host disease (GVHD) with 75% (n¼6) diagnosedprior to the onset of NTM. Overall survival was 73%(n¼8).
Causes of death were: complications due to NTM, progres-
sive underlying disease, and pulmonary failure secondary to
chronic GVHD. Of the 8 surviving pts, 1 had recurrence, 5
cleared the infection, and 2 are in treatment.
No statistically signiﬁcant risk factors for NTM were
found, including presence of GVHD, CD4 count at diagnosis,
CMV viremia, or donor source. Similar results were obtained
when not controlling for these variables. No statistically
signiﬁcant difference was found between pts who developed
MAC infections and those that did not.
Discussion: These results were unable to identify low CD4
counts as a potential risk factor for NTM necessitating the
need for multicenter collaborations. NTM appears to be a
treatable disease, with the role of prophylaxis unclear. With
the extensive treatment duration, healthcare utilization costs
should also be evaluated.281
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Hematopoietic Stem Cell Transplantation (HSCT) plays an
important role in the treatment of children with Acute
Myeloid Leukemia (AML). Match related donor (MRD) and
Unrelated Cord Blood Transplantation (UCBT) for patients
who lack a sibling donor are the options of HSCT in our unit.
UCB offers the advantage of faster availability of banked
cryopreserved UCB units compared with unrelated bone
marrow grafts with similar results in survival. We report our
results of HSCT for AML. We analyzed 28 children receiving
allogeneic HSCT for AML, 17 UCBT and 11 HSCT from a MRD.
Cord blood units were selected with 1 or 2 HLA mismatch;
reduce intensity conditioning (RIC) in all except two UCBT
consists of ﬂudaradine andmelphalan. Conditioning for MRD
HSCT consists of BU16/Cy120. Graft vs host disease prophy-
laxis with cyclosporine/MTX for MRD HSCT and cyclo-
sporine/MMF o cyclosporine/methylprednisolone for UCBT.
Average for neutrophil recovery in UCBT and MRD HSCT was
21 and 19 days respectively, average for platelet recovery in
UCBT and MRD HSCT was 34 and 23 days respectively.
Transplant related mortality in UCBT and MRD HSCT 18% and
17% respectively, causes of death were relapse(5¼29%) grade
IV hepatic graft versus host disease(2) and bacterial sepsis(1)
for UCBT, causes of death in MRD HSCT were relapse (1¼9%)
cerebral infarction(1) and chronic graft versus host dis-
ease(1). With a median follow up of 1 year, overall survival
for entire cohort was 60.7%, overall survival for UCBT was
52.9% and 72.7% for MRD HSCT (p¼0.25). Despite being few
patients these results show no signiﬁcant difference in
overall survival between related donors and unrelated cord
blood. RIC with ﬂudarabine and melphalan is a promising
alternative in children; it shows an acceptable relapse rate
compared with other more toxic conditionings.282
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